Research programme: nitric oxide synthase type II inhibitors - Bayer HealthCare Pharmaceuticals/Pharmacopeia Drug Discovery
Alternative Names: Inducible nitric oxide synthase inhibitors - Bayer HealthCare Pharmaceuticals/Pharmacopeia; iNOS inhibitors - Bayer HealthCare Pharmaceuticals/Pharmacopeia; PS 891169; Research programme: inducible nitric oxide synthase inhibitors - Bayer HealthCare Pharmaceuticals/PharmacopeiaLatest Information Update: 11 Jul 2007
At a glance
- Originator Pharmacopeia Drug Discovery
- Developer Bayer HealthCare Pharmaceuticals; Pharmacopeia
- Class Small molecules
- Mechanism of Action Nitric oxide synthase type II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Rheumatoid arthritis